The agreement’s limit is 400,000 shares or 9.3 percent of the 4,311,112 shares currently outstanding.
SpineGuard has the sole discretion to determine the timing of the funding. While the agreement secures the company’s financial resources, it does not reflect an immediate need for cash.
More Articles on Devices:
SCOTUS Reverses Medtronic Patent Infringement Decision, Sides With Device Company
MicroPort Scientific to Build Training Facility for Orthopedic Business
Orthofix Names Kathleen Regan as Interim Board Chairman
